Table 1. Characteristics of 39 pooled studies evaluating the association between EMMPRIN overexpression and cancer.
| First author | Year | Country | Cancer type | Sample size | Mean age | Out comes | RR (95% CI) | Testing method | Cut-off value |
|---|---|---|---|---|---|---|---|---|---|
| Zhaodong Han1 | 2008 | China | Bladder carcinoma | 58 | 57.2± 11.2 | PFS | 3.66 (1.04-12.79) | IHC | 3+ (>51%) |
| Zhaodong Han2 | 2008 | China | Renal carcinoma | 52 | 56.8± 10.8 | PFS | 3.06 (0.82-11.44) | IHC | As above |
| Zhaodong Han3 | 2008 | China | Prostate carcinoma | 101 | 73.5± 12.3 | PFS | 4.87 (1.77-13.41) | IHC | As above |
| Zhaodong Han4 | 2008 | China | Penis carcinoma | 17 | 46.5± 9.2 | PFS | 2.38 (0.34-25.30) | IHC | As above |
| Zhaodong Han5 | 2008 | China | testis carcinoma | 17 | 48.6± 12.7 | PFS | 1.79 (0.22-19.94) | IHC | As above |
| Albrecht Stenzinger | 2011 | Germany | Colorectal cancer | 285 | 67 | OS | 3.09 (1.91-5.02) | Tissue microassay | NM |
| Jung-Woo Choi | 2014 | China | Bladder cancer | 360 | 69 | OS | 1.15 (0.50-2.67) | Tissue microassay | Scores 3 |
| WeiDe Zhong | 2010 | China | Bladder cancer | 101 | 68 | PFS/OS | 3.31 (1.07-15.72) | IHC | 1 (>10%) |
| HUI TAN | 2008 | China | Thyroid carcinoma | 156 | 46 | PFS | 3.31 (1.07-15.72) | IHC | 3+ (>51%) |
| Xiaoyan Xua | 2013 | China | Non-small cell lung cancer | 192 | 60 | OS | 6.63 (2.46-17.90) | IHC | 3+ (>51%) |
| J. Afonso | 2011 | Portugal | Bladder carcinoma | 77 | 71 | PFS/OS | 3.25 (1.02-10.39) | IHC | 1 (>5%) |
| Xinjie Yang | 2010 | China | Adenoid cystic carcinoma | 72 | 58 | OS | 2.78 (1.25-6.19) | IHC | NM |
| YauHua Yu | 2015 | America | squamous cell Carcinoma of the oral tongue | 31 | 60 | PFS/OS | 2.82 (0.60-13.26) | IHC | Grade 2 (>25%) |
| Pascale Fisel | 2015 | Germany | Clear cell renal cell Carcinoma | 186 | 64 | OS | 5.50 (2.50-12.10) | IHC | Score 3 |
| Daniel Buergy | 2009 | Germany | Colorectal cancer | 40 | 58 | OS | 2.50 (0.27-23.55) | IHC | >30% |
| Ovarian Cancer | 2007 | Finland | Ovarian cancer | 282 | 61 | PFS | 1.32 (0.98-1.80) | IHC | >10% |
| Ben Davidson | 2003 | Norway | Ovarian carcinoma | 41 | 59 | OS | 2.10 (0.76-5.81) | IHC | NM |
| Jian Gu | 2008 | China | Pediatric gliomas | 45 | 62 | PFS | 0.32 (0.11-2.09) | IHC | >51% |
| Songlin Piao | 2012 | China | Salivary duct carcinoma | 35 | 59 | PFS/OS | 2.95 (1.25-6.94) | IHC | Score 6 |
| Fangfang Liu | 2010 | China | Breast carcinoma | 110 | 53 | PFS/OS | 2.18 (0.61-7.81) | IHC | >30% |
| Antônio Talvane | 2012 | Brazil | Gastrointestinal stromal tumors | 64 | 62 | OS | 1.13 (0.24-5.25) | IHC | Score 3 |
| Min Yang | 2013 | China | Glioblastoma | 206 | 57 | OS | 2.42 (1.35-4.18) | IHC | Score 3 |
| Wei Wu | 2008 | China | Gallbladder carcinoma | 60 | 52 | OS | 0.49 (0.21-1.72) | IHC | >75% |
| Tiefu Chen | 2010 | China | Primary cutaneous Malignant melanoma | 150 | 53 | PFS/OS | 7.32 (1.19-20.29) | IHC | >10% |
| YiJun Xue | 2011 | China | Bladder cancer | 118 | 58 | OS | 2.33 (1.15-4.73) | IHC | >51% |
| Ying Liu | 2013 | China | Basal-like breast cancer | 126 | 56 | PFS/OS | 5.41 (0.74-39.49) | IHC | NM |
| Shaojun Zhu1 | 2013 | China | Colorectal cancer | 163 | 53 | OS | 8.88 (5.52-14.82) | IHC | Score 3 |
| Shaojun Zhu2 | 2013 | China | Colorectal cancer | 194 | 53 | OS | 3.51 (2.03-6.08) | IHC | As above |
| Shaojun Zhu3 | 2013 | China | Colorectal cancer | 213 | 53 | OS | 1.89 (1.06-3.38) | IHC | As above |
| Zhaodong Han1 | 2009 | China | Prostate Cancer | 39 | 74 | OS | 4.49 (0.29-69.18) | IHC | Score 2 (>25%) |
| Zhaodong Han2 | 2009 | China | Prostate Cancer | 34 | 74 | OS | 3.54 (0.24-51.94) | IHC | As above |
| Che Zhang | 2010 | China | Intrahepatic Cholangiocarcinoma | 49 | 66 | OS | 0.98 (0.76-2.01) | IHC | >51% |
| Tongwei Chu | 2011 | China | Pediatric Medulloblastoma | 55 | 59 | OS | 3.50 (1.60-5.10) | IHC | Grade 2 (>10%) |
| Xiaoxia Gou | 2014 | China | Laryngeal | 48 | 64 | OS | 4.87 (0.47-23.50) | IHC | Score 3 |
| Xinwen Zhong | 2013 | China | Pulmonary Adenocarcinoma | 180 | 68 | OS | 2.01 (1.26-3.21) | IHC | Score 3 (>51%) |
| K Boye | 2012 | Norway | Colorectal cancer | 277 | NR | OS | 3.30 (1.40-7.80) | IHC | Score 2 (>25%) |
| Luís SilvaMonteiro | 2014 | Portugal | Oral Squamous Cell Carcinomas | 74 | 62 | OS | 3.89 (1.11-13.71) | IHC | Score 5 |
| XingZhu Ju | 2008 | China | Cervical Cancer | 82 | 52 | PFS | 1.23 (0.52-2.90) | IHC | >51% |
| XinQiong Huang | 2014 | China | Cervical Cancer | 132 | 51 | PFS | 5.12 (2.56-12.78) | IHC | >25% |
| LingMin Kong | 2011 | China | Hepatocellular carcinoma | 54 | 60 | OS | 2.13 (0.78-5.79) | Tissue microassay | Score 3 |
| Shu Zhao | 2013 | China | Ttriple-negative breast cancer | 127 | 47 | OS | 2.68 (1.08-6.66) | IHC | NM |
| Li Tian1 | 2013 | China | Astrocytic glioma | 182 | 65 | OS | 2.57 (1.41-4.83) | IHC | Score 3 |
| Li Tian2 | 2014 | China | Astrocytic glioma | 151 | 65 | OS | 4.52 (2.88-10.96) | IHC | As above |
| Li Tian3 | 2015 | China | Astrocytic glioma | 125 | 65 | OS | 6.61 (3.62-13.21) | IHC | As above |
| Dake Chu | 2013 | China | Gastric cancer | 223 | 60 | PFS/OS | 1.59 (1.05-2.40) | IHC | Score 3 |
| Weide Zhong | 2012 | China | Prostate cancer | 240 | 62 | OS | 3.08 (1.62-5.85) | Tissue microassay | NM |
| Shaojun Zhu | 2015 | China | Hepatocellular carcinoma | 50 | 65 | PFS | 2.41 (1.61-13.70) | IHC | >25% |
| Quan Zhou | 2011 | China | Osteosarcoma | 65 | 55 | PFS/OS | 5.33 (0.57-49.56) | IHC | >51% |
NR: not reporte; IRS: immunoreactivity score.